• Type of startup : Life Sciences, TIC
  • Date of entry : 11/05/2021
  • Date of exit : 11/11/2022
  • Associated laboratory(ies) : Hôpital Ste Musse de Toulon, APHM de Marseille
  • See the website

M-DT1’s ambition is to develop a digital approach to blood glucose management for type 1 diabetes patients, so as to be recognized as a capitalizable company driving excellence and expertise.

So our company is positioned as developing innovative solutions both for the end user (the patient) and upstream of this value chain for the various manufacturers and market players involved.

Our project aims to bring a thus far non-existent element to the features of continuous blood sugar monitors and insulin pumps or artificial pancreases (sometimes associated with them).